Lene Kristine Juvet

Lene Kristine Juvet

Auto-generated profile, based on publicly available information

Lene Kristine Juvet

Norwegian Institute of Public Health Oslo Norway

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2023 in Vaccine
Verified
Journal Article
Open access
LTLill Trogstad
Lill Trogstad
ILIda Laake
Ida Laake
ARAnna H. Robertson
Anna H. Robertson
SMSiri Mjaaland
Siri Mjaaland
ICIda H. Caspersen
Ida H. Caspersen
BFBerit Feiring
Berit Feiring
Many signals of menstrual disturbances as possible side effects of vaccination against COVID-19 have been reported. Our objective was to compare the risk of menstrual disturbances before and after vaccination among women aged 18-30 years in Oslo, Norway. We used electronic questionnaires to collect reports of menstrual disturbances from 3972 women aged 18-30 years, participating in the population-based Norwegian Young Adult Cohort. We examined the occurrence of menstrual disturbances (heavier bleeding than usual, prolonged bleeding, shorter interval between menstruations, longer interval between menstruations, spot bleedings, stronger pain during menstruation, period pain without bleeding) before and after the first and second dose of COVID-19 vaccine. Relative risks (RR) according to vaccination were estimated using a self-controlled case-series design. We performed additional analyses stratified by vaccine brand, contraception/hormone use, and presence of gynecological condition(s). The prevalence of any menstrual disturbance was 36.7 % in the last menstrual cycle prior the first vaccine dose. The RR for heavier bleeding than usual was 1.90 (95 % CI: 1.69-2.13) after the first vaccine dose and 1.84 (95 % CI 1.66-2.03) after the second dose. Increased risks of prolonged bleeding, shorter interval between menstruations, and stronger pain during menstruation were also observed after both doses. The RRs did not differ with vaccine brand, contraception/hormone use, or presence of gynecological condition(s) for any of the menstrual disturbances. Menstrual disturbances were common regardless of vaccination. We found increased risk of menstrual disturbances after vaccination, particularly for heavier bleeding than usual, prolonged bleeding, shorter interval between menstruations, and stronger period pain. In the future, menstrual characteristics should be included in vaccine trials.

19 October 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
ILIda Laake
Ida Laake
SSSiri N Skodvin
Siri N Skodvin
KBKristine Blix
Kristine Blix
ICIda Henriette Caspersen
Ida Henriette Caspersen
HGHåkon K. Gjessing
Håkon K. Gjessing
BFBerit Feiring
Berit Feiring
Background: Understanding how booster vaccination can prevent moderate and severe illness without hospitalization is crucial to evaluate the full advantage of mRNA boosters. Methods: We followed 85 801 participants (aged 31–81 years) in 2 large population-based cohorts during the Omicron BA.1/2 wave. Information on home testing, PCR testing, and symptoms of coronavirus disease 2019 (COVID-19) was extracted from biweekly questionnaires covering the period 12 January 2022 to 7 April 2022. Vaccination status and data on previous SARS-CoV-2 infection were obtained from national registries. Cox regression was used to estimate the effectiveness of booster vaccination compared to receipt of 2-dose primary series >130 days previously. Results: The effectiveness of booster vaccination increased with increasing severity of COVID-19 and decreased with time since booster vaccination. The effectiveness against severe COVID-19 was reduced from 80.9% shortly after booster vaccination to 63.4% in the period >90 days after vaccination. There was hardly any effect against mild COVID-19. The effectiveness tended to be lower among subjects aged ≥60 years than those aged <50 years. Conclusions: This is the first population-based study to evaluate booster effectiveness against self-reported mild, moderate, and severe COVID-19. Our findings contribute valuable information on duration of protection and thus timing of additional booster vaccinations.

22 September 2023 in Science Advances
Verified
Journal Article
Open access
KBKristine Blix
Kristine Blix
ILIda Laake
Ida Laake
LJLene Juvet
Lene Juvet
ARAnna Hayman Robertson
Anna Hayman Robertson
ICIda Henriette Caspersen
Ida Henriette Caspersen
LTLill Trogstad
Lill Trogstad
The association between coronavirus disease 2019 (COVID-19) vaccination and vaginal bleeding among nonmenstruating women is not well studied. The Norwegian Institute of Public Health followed several cohorts throughout the pandemic and early performed a systematic data collection of self-reported unexpected vaginal bleeding in nonmenstruating women. Among 7725 postmenopausal women, 7148 perimenopausal women, and 7052 premenopausal women, 3.3, 14.1, and 13.1% experienced unexpected vaginal bleeding during a period of 8 to 9 months, respectively. In postmenopausal women, the risk of unexpected vaginal bleeding (i.e., postmenopausal bleeding) in the 4 weeks after COVID-19 vaccination was increased two- to threefold, compared to a prevaccination period. The corresponding risk of unexpected vaginal bleeding after vaccination was increased three- to fivefold in both nonmenstruating peri- and premenopausal women. In the premenopausal women, Spikevax was associated with at 32% increased risk as compared to Comirnaty. Our results must be confirmed in future studies.

16 September 2026 in Reviews in Medical Virology
Verified
Journal Article
Open access
EHE. Heen
E. Heen
JØJoakim Øverbø
Joakim Øverbø
ITI. H. Tveteraas
I. H. Tveteraas
SSS. L. Solberg
S. L. Solberg
HNH. Nøkleby
H. Nøkleby
LJL. K. Juvet
L. K. Juvet
Herpes zoster (HZ, shingles) constitutes a significant public health concern, particularly in ageing populations, and there is growing global interest in the recombinant zoster vaccine (RZV) from a public health perspective. In this systematic review with meta‐analysis, we assessed the efficacy and effectiveness of RZV against HZ and its complications, including a possible association with a reduced risk of dementia, among immunocompetent individuals aged 50 years and older. We synthesised the latest evidence on long‐term effects, incorporating recent data from both trials and real‐world effectiveness studies. A total of 27 publications based on 18 primary studies, 3 randomised controlled trials (RCTs) and 15 observational studies, were included. RZV provides very high protection against HZ in immunocompetent adults ≥ 50 years in RCTs, with approximately 95% efficacy and high certainty of evidence (CoE) according to GRADE. Observational studies also consistently indicate substantial protection, but effect estimates vary across settings (high CoE). Among vaccinated individuals who develop HZ, RZV is associated with reduced loss of quality of life and decreased analgesic use. The vaccine also substantially reduces the risk of herpes zoster ophthalmicus (HZO) (high CoE) and likely postherpetic neuralgia (PHN) (moderate CoE). Long‐term follow‐up suggests durable protection for at least 11 years (low CoE). RZV may be associated with a reduced risk of dementia (low CoE), due to uncertainty the true effect may be substantially different, and similar associations have been observed with other vaccines and may be confounded by healthy vaccinee bias.

30 April 2026 in BMC Public Health
Verified
Journal Article
Open access
PDF file
RGRebecca Nybru Gleditsch
Rebecca Nybru Gleditsch
SWSara Viksmoen Watle
Sara Viksmoen Watle
BHBo Terning Hansen
Bo Terning Hansen
LNLisbeth Meyer Næss
Lisbeth Meyer Næss
LJLene Kristine Juvet
Lene Kristine Juvet
TOTrine Skogset Ofitserova
Trine Skogset Ofitserova
Background: As one of few countries in Europe, Norway does not offer vaccination against invasive meningococcal disease (IMD) as part of the National Immunization Program for Children (NIP). Instead, adolescents aged 16–19 are recommended to consider having the meningococcal ACWY conjugate vaccine (MCV4) if they participate in activities that increase the risk of IMD. Meningococcal vaccination rates in Norway are low compared to vaccines offered through the NIP. Whereas all vaccinations in the NIP are free and organized through schools or municipal health clinics, there is no uniform system in place for the meningococcal vaccine. On the contrary, both administration practices and cost of vaccination vary nationally, with some counties offering the vaccine for free, while others offer the vaccine at a cost of $40–80. The aim of this study was to explore adolescents’ awareness, knowledge, and decision-making processes related to meningococcal disease and vaccination. Methods: Using a semi-structured interview guide, we conducted 18 focus group interviews in the fall of 2022, involving a total of 126 high school seniors in Norway. The participants were asked to share their views, knowledge and experiences regarding invasive meningococcal disease and vaccination. We used NVivo 14 to facilitate the thematic analysis and a codebook analysis approach was conducted to identify themes and patterns in the data. Results: The analysis identified three central themes emerging from the discussions with the adolescents. These emphasize how information, cost, and location and guidance impact the adolescents’ decision-making and ability to get vaccinated. Conclusions: The current organization of MCV4 vaccination in Norway do not meet the needs identified by the adolescents in this study. This results in unequal access to a highly effective vaccine that protects healthy adolescents against a deadly disease. The present study highlights the need to address vaccination disparities and accessibility, as well as increasing awareness and knowledge about meningococcal disease and vaccination to ensure equal access for all adolescents.

21 August 2023 in medRxiv
Verified
Preprint
Open access
PDF file
LCLouis Yat Hin Chan
Louis Yat Hin Chan
GRGunnar Rø
Gunnar Rø
JMJørgen Eriksson Midtbø
Jørgen Eriksson Midtbø
FRFrancesco Di Ruscio
Francesco Di Ruscio
SWSara Sofie Viksmoen Watle
Sara Sofie Viksmoen Watle
BBBirgitte Freiesleben de Blasio
Birgitte Freiesleben de Blasio
Vaccination was a key intervention in controlling the COVID-19 pandemic globally. In early 2021, Norway faced significant regional variations in COVID-19 incidence and prevalence, with large differences in population density, necessitating efficient vaccine allocation to reduce infections and severe outcomes. This study explored alternative vaccination strategies to minimize health outcomes (infections, hospitalizations, ICU admissions, deaths) by varying regions prioritized, extra doses prioritized, and implementation start time. Using two models (individual-based and meta-population), we simulated COVID-19 transmission during the primary vaccination period in Norway, covering the first 7 months of 2021. We investigated alternative strategies to allocate more vaccine doses to regions with a higher force of infection. We also examined the robustness of our results and highlighted potential structural differences between the two models. Our findings suggest that early vaccine prioritization could reduce COVID-19 related health outcomes by 8% to 20% compared to a baseline strategy without geographic prioritization. For minimizing infections, hospitalizations, or ICU admissions, the best strategy was to initially allocate all available vaccine doses to fewer high-risk municipalities, comprising approximately one-fourth of the population. For minimizing deaths, a moderate level of geographic prioritization, with approximately one-third of the population receiving doubled doses, gave the best outcomes by balancing the trade-off between vaccinating younger people in high-risk areas and older people in low-risk areas. The actual strategy implemented in Norway was a two-step moderate level aimed at maintaining the balance and ensuring ethical considerations and public trust. However, it did not offer significant advantages over the baseline strategy without geographic prioritization. Earlier implementation of geographic prioritization could have more effectively addressed the main wave of infections, substantially reducing the national burden of the pandemic. Author summary We utilized two geographic-age-structured models (an individual-based model and a meta-population model) to conduct a scenario-based analysis aimed at evaluating strategies for geographic prioritization of COVID-19 vaccines in Norway. By reconstructing the dynamics of COVID-19 transmission from January to July of 2021, we compared various alternative vaccination strategies through model simulations, given the limited number of vaccine doses. We found that prioritization of vaccines based on geographic location, alongside considering age, was preferable to a baseline strategy without geographic prioritization. We assessed the selection of which municipalities to prioritize and the degree of prioritization they should receive. Our findings indicated that optimal strategies depended on whether the aim was to minimize infections, hospitalizations, ICU admissions, or deaths. Trade-offs in infection growth between municipalities and subsequent risk-class allocations (such as age groups) were the primary factors influencing optimal vaccine allocation. Furthermore, we found that earlier implementation of most geographic prioritization strategies was advantageous in reducing the overall burden of COVID-19.